Fate Therapeutics Inc. started an underwritten public offering of its common stock.
The net proceeds will be used for clinical development and research activities, working capital and other general corporate purposes.
Leerink Partners LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering.
